London Biotech Startup Raises £3.6m to Revolutionize Drug Development
The world of medicine and drug development is constantly evolving, with new technologies and innovations emerging every day. One such innovation is the use of artificial intelligence (AI) to develop next-generation drugs. And leading the charge in this field is London-based biotech startup, Ternary Therapeutics.
Ternary Therapeutics has recently made headlines by raising an impressive £3.6m in funding to scale its AI-powered platform. This platform is designed to engineer molecular glue medicines that target previously undruggable proteins, opening up a whole new world of possibilities in the treatment of diseases.
The company’s success in securing this funding is a testament to the potential of its technology and the confidence of investors in its capabilities. With this injection of funds, Ternary Therapeutics is set to make significant strides in the development of next-generation drugs.
So, what exactly is Ternary Therapeutics and how does its AI-powered platform work? Let’s take a closer look.
Founded in 2019, Ternary Therapeutics is a biotech startup that is revolutionizing the drug development process. Its AI-powered platform uses cutting-edge technology to engineer molecular glue medicines that target proteins that were previously considered “undruggable”. These proteins play a crucial role in various diseases, but traditional drug development methods have been unable to target them effectively.
Ternary’s platform utilizes a unique approach that combines AI, computational chemistry, and molecular modeling to identify and design small molecules that can bind to these undruggable proteins. These molecules act as “glue” that bring together the target protein and another protein, leading to its degradation and ultimately, the treatment of the disease.
This innovative approach has the potential to revolutionize the treatment of a wide range of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. And with the recent funding, Ternary Therapeutics is now in a position to scale its platform and bring these next-generation drugs to the market.
The £3.6m raised by Ternary Therapeutics was led by the UK Innovation & Science Seed Fund (UKI2S) and private investors. This funding will be used to expand the company’s team, accelerate the development of its platform, and advance its drug discovery programs.
Commenting on the funding, Ternary’s CEO, Dr. Mark Gurney, said, “We are thrilled to have the support of UKI2S and our private investors as we work towards our goal of developing transformative medicines for patients in need. This funding will enable us to expand our team and accelerate the development of our AI-powered platform, bringing us one step closer to revolutionizing the treatment of diseases.”
The success of Ternary Therapeutics is a testament to the growing interest and investment in the field of AI-powered drug development. With the potential to target previously undruggable proteins, this technology has the power to transform the treatment of diseases and improve the lives of patients worldwide.
In addition to its innovative platform, Ternary Therapeutics also prides itself on its diverse and highly skilled team. The company’s team consists of experts in AI, computational chemistry, and drug development, all working together towards a common goal of advancing the field of medicine.
Ternary Therapeutics is also a strong advocate for diversity and inclusion in the biotech industry. The company’s leadership team is made up of 50% women, and they are committed to promoting diversity and equality within the company and the industry as a whole.
The future looks bright for Ternary Therapeutics, and with the support of its investors, the company is poised to make a significant impact in the world of medicine. The potential of its AI-powered platform is immense, and it is only a matter of time before we see the first next-generation drug developed by Ternary hit the market.
In conclusion, Ternary Therapeutics is a shining example of the potential of AI in drug development. With its innovative platform and dedicated team, the company is on a mission to transform the treatment of diseases and improve the lives of patients worldwide. We can’t wait to see what the future holds for this London biotech startup.
